BenevolentAI harnesses artificial intelligence to enhance and accelerate scientific discovery by making sense of highly fragmented information to create new insights and usable knowledge that benefit society. The Company's mission is to bring the power of humans and machines together to make sense of, and drive rapid scientific discovery. Its proprietary AI technology, the Judgement Augmented Cognition System (JACS) uses cutting edge deep learning techniques to change the way knowledge is created, connected and applied, and enables the mass analysis of vast amounts of scientific information.
Type
Private
HQ
London, GB
Founded
2013
Size (employees)
104 (est)+15%
BenevolentAI was founded in 2013 and is headquartered in London, GB
Report incorrect company information

Key People/Management at BenevolentAI

Jackie Fmedsc

Jackie Fmedsc

Director
Kenneth Mulvany

Kenneth Mulvany

Director
Jerome Pesenti

Jerome Pesenti

Non-Executive Director
Bart Swanson

Bart Swanson

Non-Executive Director
Joanna Shields

Joanna Shields

Group CEO
Amir Saffari

Amir Saffari

SVP Artificial Intelligence
Show more

BenevolentAI Office Locations

BenevolentAI has offices in New York and London
London, GB (HQ)
40 Churchway
New York, US
222 Broadway
Show all (2)
Report incorrect company information

BenevolentAI Financials and Metrics

Summary Metrics

Founding Date

2013

Total Funding

$215 m

Latest funding size

$115 m

Time since last funding

a month ago

Investors

BenevolentAI's latest funding round in April 2018 was reported to be $115 m. In total, BenevolentAI has raised $215 m. BenevolentAI's latest valuation is reported to be $1 b.
Show all financial metrics

BenevolentAI Financials

Market valuation

1 b
Show all financial metrics

BenevolentAI Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
Proximagen
Report incorrect company information

BenevolentAI News and Updates

Algorithms vs Alzheimers? BenevolentAI Hits $2B High

Some 76 startups now using AI in drug discovery - with traditional discovery then route to market typically taking over a decade The post Algorithms vs Alzheimers? BenevolentAI Hits $2B High appeared first on Computer Business Review.

Woodford-backed BenevolentAI raises $115m as founder allays robot fears

The founder of artificial intelligence (AI) startup BenevolentAI believes robots will be able to exist in a symbiotic relationship with humans, refuting the idea that they will replace all jobs. Speaking to City A.M., Ken Mulvany said AI will "multiply the power of our intellect" in the same way …

UPDATE 1-AI drug hunter BenevolentAI worth $2 bln after fund raising

LONDON, April 19 (Reuters) - BenevolentAI, a British drug developer that uses artificial intelligence to identify new medicine candidates, said it had raised $115 million in a funding round that valued it at $2 billion.

UK drug discovery startup BenevolentAI raises $115M

U.K.-based artificial intelligence company BenevolentAI Ltd. today announced the completion of a $115 million funding round that values the London startup at a cool $2 billion. The round, said to be one of the largest ever in the AI pharmaceutical sector, was led by BevenolentAI’s existing backers i…

BenevolentAI, which uses AI to develop drugs and energy solutions, nabs $115M at $2B valuation

In the ongoing race to build the best and smartest applications that tap into the advances of artificial intelligence, a startup out of London has raised a large round of funding to double down on solving persistent problems in areas like healthcare and energy . BenevolventAI announced today that it…

A startup that uses artificial intelligence to discover new drugs just landed a $2 billion valuation

UK-based biotech unicorn BenevolentAI just raised $115 million at a $2 billion valuation. The company uses artificial intelligence to help discover new drugs to treat conditions like Parkinson's disease and rare cancers.  Applying artificial intelligence to drug discovery — which can often be a l…
Show more
Report incorrect company information